等待開盤 10-23 09:30:00 美东时间
+0.750
+14.15%
今日重点评级关注:Canaccord Genuity:维持ATAI Life Sciences"买入"评级,目标价从11美元升至14美元;麦格理:维持Cleanspark"跑赢大市"评级,目标价从20美元升至30美元
29分钟前
Citigroup analyst Samantha Semenkow upgrades Bioage Labs (NASDAQ:BIOA) from Neutral to Buy and raises the price target from $5 to $10.
10-22 19:21
STOCKHOLM, Oct. 14, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanem...
10-14 13:14
BioCryst Pharmaceuticals has agreed to acquire Astria Therapeutics for approximately $700 million in enterprise value, with the aim of adding Astria's Phase 3 HAE drug candidate, navenibart, to its portfolio. The deal is expected to solidify double-digit growth for BioCryst's HAE division over the next decade and maintain profitability. Navenibart is a long-acting, injectable therapy with a differentiated dosing schedule, addressing unmet needs i...
10-14 11:00
Biomerica Inc. appoints Gary Huff as an independent board member, leveraging his extensive experience in diagnostics, healthcare, and leadership. Huff, former CEO of LabCorp Diagnostics, brings a proven track record of commercial success and strategic vision. Biomerica highlights his ability to drive growth and innovation, particularly in advancing its inFoods® IBS product, a diagnostic-guided therapy for irritable bowel syndrome showing promisin...
10-08 12:19
STOCKHOLM, Oct. 6, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: Leqembi Iq...
10-07 06:02
BioArctic AB Class B ( ($SE:BIOA.B) ) has shared an announcement. BioArctic AB’...
10-07 05:04
BioAge Labs (NASDAQ:BIOA) files $250M mixed securities shelf. This prospectus is not an offer to sell these securities. Filing More on Powell Industries: From Backlog Boom To Growth Bust Polygon Stead...
10-03 04:42
STOCKHOLM, Sept. 24, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved lecanemab...
09-24 14:56
BioArctic AB Class B ( ($SE:BIOA.B) ) has provided an update. BioArctic AB anno...
09-04 00:05